Holen Sie sich die Stockscreener-App
0.436
5.22%
-0.024
Handel nachbörslich:
.41
-0.026
-5.96%
Nextcure Inc Aktie (NXTC) Neueste Nachrichten
Nextcure Inc: Analyzing NXTC Stock Trends - investchronicle.com
Market Recap: Next Technology Holding Inc (NXTT)’s Positive Momentum, Closing at 1.40 - DWinneX
Market Highlights: Nextcure Inc (NXTC) Ends on a Low Note at 0.50 - DWinneX
NextCure tanks as it teams up with Simcere on novel ADC - The Pharma Letter
NextCure and Simcere partner to develop SIM0505 for solid tumours - Yahoo Finance
NextCure partners with Simcere Zaiming on cancer drug development By Investing.com - Investing.com South Africa
NextCure Joins China-ADC Gold Rush with $745M Simcere Deal - BioSpace
NextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% Decline - Asianet Newsable
NextCure And Simcere Zaiming Partner To Develop CDH6-Targeting ADC SIM0505 For Solid Tumors - Nasdaq
NextCure signs up to $745 million deal with China's Simcere to develop cancer drug - MarketScreener
Simcere Pharmaceutical's Unit Enters Into License Agreement With Nextcure - marketscreener.com
NextCure Enters Licensing Agreement with Simcere Zaiming - TipRanks
NextCure (NXTC) Partners with Simcere Zaiming for Innovative Cancer Treatment | NXTC Stock News - GuruFocus
NextCure partners with Simcere Zaiming on cancer drug development - Investing.com Australia
Nextcure And Simcere Zaiming Announce Strategic Partnership For A Novel Antibody-Drug Conjugate Targeting CDH6 - marketscreener.com
Simcere Enters Strategic License Agreement with NextCure for Oncology Advancements - TipRanks
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6 - GlobeNewswire
NextCure Lands Massive $745M Deal for Revolutionary Cancer Drug: Phase 1 Trials Starting Q3 2025 - Stock Titan
Guardian Capital Announces June 2025 Cash Distributions for Guardian Capital ETFs - The Globe and Mail
Billionaire Terry Smith, "the English Warren Buffett," Is Selling Meta Platforms and Microsoft and Buying This Stock That's Trouncing the Market in 2025 - The Globe and Mail
Is Lucid Stock a Millionaire-Maker? - The Globe and Mail
JD.com Underperforms Industry in 3 Months: Should You Book Profits? - The Globe and Mail
Whitbread (LON:WTB) Stock Price Crosses Above Two Hundred Day Moving Average – What’s Next? - Defense World
Better Energy Stock: TotalEnergies vs. Chevron - The Globe and Mail
Can Shopify's Expanding Merchant Base Sustain Its Growth Momentum? - The Globe and Mail
Baidu Bets Big on AI: Is the Cloud Business Finally Paying Off? - The Globe and Mail
SFIX Q3 Loss Narrower Than Expected, FY25 Outlook Raised, Stock Up 8% - The Globe and Mail
COIN Outpaces Industry in 3 Months: Time to Buy the Stock? - The Globe and Mail
Power Corporation's President and Chief Executive Officer R. Jeffrey Orr to speak at the Scotiabank Financials Summit - The Globe and Mail
Pre-market Movers: LIMN, KRON, HSDT, CBUS... - RTTNews
Best Dollar Store Stock to Buy: Dollar Tree or Dollar General? - The Globe and Mail
2 No-Brainer Growth Stocks to Buy in June - The Globe and Mail
The Next Stock I'm Buying? - The Globe and Mail
NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024 - Insider Monkey
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025 - The Manila Times
NextCure, Inc. and LigaChem Biosciences Announce Phase 1 Study of LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, to be Presented at ASCO 2025 - Nasdaq
First-in-Human Trial: NextCure's Revolutionary Cancer Drug Shows Promise Against 5 Hard-to-Treat Tumors - Stock Titan
Pre-market Movers: ALZN, HCTI, REVB, NTLA... - RTTNews
Kura Oncology, Inc. (KURA) and Kyowa Kirin to Present Promising Ziftomenib Data at ASCO 2025 - Yahoo Finance
Here's How I'd Invest $10,000 Today - The Globe and Mail
Grant Williamson appointed as Canada Leader for Willis - The Globe and Mail
Jim Cramer Says You Should Buy This ‘Strong Buy’ Stock ‘Hand Over Fist’ - The Globe and Mail
Is Enbridge Stock Still Worth Owning After Strong Q1 Earnings? - The Globe and Mail
Is Archer Aviation Stock (ACHR) a “Buy” Ahead of Q1 Earnings? - The Globe and Mail
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results - The Manila Times
NextCure Inc reports results for the quarter ended March 31Earnings Summary - TradingView
NextCure Reports Q1 2025 Results and Strategic Progress - TipRanks
NextCure (NXTC) Advances LNCB74 Program in Phase 1 Study | NXTC Stock News - GuruFocus
NextCure, Inc. SEC 10-Q Report - TradingView
NextCure Expands Cancer Drug Trial to 13 Sites as Phase 1 ADC Study Hits Key Milestone - Stock Titan
NextCure Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Is Nextcure Inc’s -69.93% Fall This Year Is A Better Investing Opportunity? - Marketing Sentinel
Press Release Distribution & PR Platform - ACCESS Newswire
Should You Buy Nvidia Stock on the ‘Liberation Day’ Dip? - The Globe and Mail
NextCure Updates Presentation on LNCB74 Clinical Trial - TipRanks
NextCure stock hits 52-week low at $0.3 amid sharp decline - Investing.com Australia
NextCure stock hits 52-week low at $0.3 amid sharp decline By Investing.com - Investing.com South Africa
2seventy, TG, Springworks lead cancer index among Q1 market falls - BioWorld MedTech
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Cancer Therapy Breakthrough? NextCure's Major Presentation at Needham Healthcare Conference - Stock Titan
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):